Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.clineuro.2020.106451 http://scihub22266oqcxt.onion/10.1016/j.clineuro.2020.106451 33388661!7831713!33388661     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Neurol+Neurosurg 2021 ; 201 (ä): 106451 Nephropedia Template TP {{tp|p=33388661|t=2021. SARS-CoV-2/COVID-19 in multiple sclerosis patients receiving disease-modifying therapy |pdf=|usr=}}{{33388661}} gab.com Text SARS-CoV-2/COVID-19 in multiple sclerosis patients receiving disease-modifying therapy JO: Clin Neurol Neurosurg http://www.kidney.de/pget.php?&tw=1&pmid=33388661 #FOAvip At the end of 2019, the COVID-19 pandemic began, which at the time of writing continues to be a serious problem for many areas of medicine, including neurology. Since patients with multiple sclerosis (MS) often exhibit motor disability and receive disease-modifying therapy (DMT), which has an immunosuppressive effect, it is plausible that this will affect the susceptibility of MS patients to COVID-19, as well as the course of this disease. However, current data indicate that the use of DMT does not cause negative prognosis in COVID-19 sufferers, but the motor disability progression associated with MS does. In this study, we present the case reports of 4 patients with relapsing-remitting MS, who developed COVID-19, and despite the use of DMT the course of the disease was mild. Two patients were treated with dimethyl fumarate, one with Interferon beta1b and one with glatiramer acetate. One of the patients using dimethyl fumarate had lymphopenia. All patients had symptoms of COVID-19 from the nervous system, the most frequent being headache, which occurred in all patients. The aim of this article is to present a case series of four patients with MS and COVID-19, and to discuss the available literature on COVID-19 in patients with MS, with particular consideration of the impact of DMT. Twit Text FOAVip SARS-CoV-2/COVID-19 in multiple sclerosis patients receiving disease-modifying therapy ????Clin Neurol Neurosurg http://www.kidney.de/pget.php?&tw=1&pmid=33388661 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33388661 #FOAvip English Wikipedia <ref>{{Cite pmid|33388661}}</ref> SARS-CoV-2/COVID-19 in multiple sclerosis patients receiving disease-modifying therapy #MMPMID33388661 Adamczyk-Sowa M; Mado H; Kubicka-Baczyk K; Jaroszewicz J; Sobala-Szczygiel B; Bartman W; Sowa P Clin Neurol Neurosurg 2021[Feb]; 201 (ä): 106451 PMID33388661show ga At the end of 2019, the COVID-19 pandemic began, which at the time of writing continues to be a serious problem for many areas of medicine, including neurology. Since patients with multiple sclerosis (MS) often exhibit motor disability and receive disease-modifying therapy (DMT), which has an immunosuppressive effect, it is plausible that this will affect the susceptibility of MS patients to COVID-19, as well as the course of this disease. However, current data indicate that the use of DMT does not cause negative prognosis in COVID-19 sufferers, but the motor disability progression associated with MS does. In this study, we present the case reports of 4 patients with relapsing-remitting MS, who developed COVID-19, and despite the use of DMT the course of the disease was mild. Two patients were treated with dimethyl fumarate, one with Interferon beta1b and one with glatiramer acetate. One of the patients using dimethyl fumarate had lymphopenia. All patients had symptoms of COVID-19 from the nervous system, the most frequent being headache, which occurred in all patients. The aim of this article is to present a case series of four patients with MS and COVID-19, and to discuss the available literature on COVID-19 in patients with MS, with particular consideration of the impact of DMT. |*COVID-19 Drug Treatment[MESH] |Adult[MESH] |COVID-19/*complications/diagnostic imaging[MESH] |Female[MESH] |Humans[MESH] |Immunosuppressive Agents/pharmacology/*therapeutic use[MESH] |Middle Aged[MESH]SARS-CoV-2/COVID-19 in multiple sclerosis patients receiving disease-m(epmc).pdf DeepDyve Pubget Overpricing